Stocks News

LAST PRICE
57.7900
TODAY'S CHANGE (%)
Trending Down-1.2700 (-2.1504%)

Bid / Lots
55.9800/ 1
Ask / Lots
59.5300/ 1
Open / Previous Close
59.0000 / 59.0600
Day Range
Low 57.0000
High 59.9800
52 Week Range
Low 20.8400
High 61.6630
Volume
1,166,149
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 31, 2024
- DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 07:28 ET (11:28 GMT)
Oct 30, 2024
- -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: CORT
  04:37 PM EDT, 10/30/2024 (MT Newswires) -- ...
- Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
- *DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
Oct 23, 2024
- Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
  5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
  REDWOOD CITY, Calif.--(BUSINESS WIRE)--October 23, 2024--
  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Today
- Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Rises, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: ROIV
- Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: HRMY
- -- Earnings Flash (ROIV) ROIVANT SCIENCES Reports Q2 Revenue $4.5M, from 10 hours ago by MT Newswires
  10 hours ago by MT Newswires
  Companies Mentioned: ROIV
- Stocks Down Pre-Bell After Record Highs as Earnings Season Wanes; Asia, Europe Fall, from 10 hours ago by MT Newswires
  10 hours ago by MT Newswires
  Companies Mentioned: HD, MOS, OXY, FLUT, TSN, SE, SPOT, TME, AZN, LEGN, ROIV, ONON, IGT, SHOP, SATS
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: ROIV
- Press Release: Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: ROIV
Yesterday
- DJ ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co., from 10:32AM ET on Monday Nov 11, 2024 by Dow Jones
  10:32AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: ANIP
- An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses, from 7:31AM ET on Monday Nov 11, 2024 by Dow Jones
  7:31AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: HRMY
Nov 8, 2024
- Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY, from 7:32AM ET on Friday Nov 08, 2024 by Dow Jones
  7:32AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: HRMY
- ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted, from 7:20AM ET on Friday Nov 08, 2024 by MT Newswires
  7:20AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: ANIP

Corcept Therapeutics Inc
NASDAQ:CORTUnited States

Search Criteria

Oct 31, 2024

DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 30, 2024

-- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

*DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 23, 2024

Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones

Peers Headlines

Today

Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Rises, from 9 hours ago by MT Newswires

Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY, from 9 hours ago by Dow Jones

-- Earnings Flash (ROIV) ROIVANT SCIENCES Reports Q2 Revenue $4.5M, from 10 hours ago by MT Newswires

Stocks Down Pre-Bell After Record Highs as Earnings Season Wanes; Asia, Europe Fall, from 10 hours ago by MT Newswires

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update, from 10 hours ago by Dow Jones

Press Release: Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update, from 10 hours ago by Dow Jones

Yesterday

DJ ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co., from 10:32AM ET on Monday Nov 11, 2024 by Dow Jones

An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses, from 7:31AM ET on Monday Nov 11, 2024 by Dow Jones

Nov 8, 2024

Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY, from 7:32AM ET on Friday Nov 08, 2024 by Dow Jones

ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted, from 7:20AM ET on Friday Nov 08, 2024 by MT Newswires